Home › NCT07403552

Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants

A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Participants (males and females) at least 18 years of age
* Ability to provide written informed consent
* In good heath as determined by medical evaluation,
* Willing and able to comply with trial restrictions, procedures, and requirements

Exclusion Criteria:

* Known sensitivity to any components of the IMP
* History of relevant drug hypersensitivity
* Presents or has a history of clinically significant diseases
* History of difficulty swallowing tablets or capsules.
* Any physical examination findings or medical history that might place the participant at an unacceptable risk for participation in this trial.

About the study

The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.

What is being tested

• NSHO-101 (drug)

Sponsor: Ensho Therapeutics, Inc. · Participants: 24 · Started: Jan 31, 2026

Contact the study team

• Bittoo Kanwar, MD, MD · Phone: 973-314-8995

Official record on ClinicalTrials.gov — NCT07403552

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.